Analogic Announces Middle East Introduction of its Next-Generation Checkpoint Scanner, ConneCT, at the Airport Show in Dubai
ConneCT Increases Passenger Throughput and Improves Security, Defining the Future of Airport Checkpoint Security
PEABODY, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq:ALOG), enabling the world's medical imaging and aviation security technology, today announced the Middle East debut of ConneCT(TM), a breakthrough in checkpoint security scanning technology. ConneCT is designed to dramatically improve security, lower airport screening costs, and increase passenger throughput using an upgradeable computed tomography (CT) platform that makes it easy for airports and regulators to respond to changing security and operational requirements.
With features including an open network architecture, industry-leading 3D imaging technology, and automated threat detection, ConneCT represents a transformative advancement in the security industry, comparable to the advent of the smartphone in the telecom industry.
As the recognized leader in medical and security CT technology, Analogic has leveraged its decades of imaging innovation across platforms to improve airport security. Analogic CT technology is deployed in over 1,200 airports globally for high-throughput screening of checked or hold baggage, and Analogic threat detection software has achieved the highest levels of EU and US TSA certification for hold baggage screening.
"The ConneCT has an open architecture, which will allow regulators to respond to threats much faster than current proprietary systems," said Jim Ryan, senior vice president of Security and Detection Systems. "This 'open system approach,' combined with Analogic's superior 3D imaging technology, automated threat detection software, airport friendly user interface, and streamlined design, will give airports in the Middle East the world-class security solution they require."
"We are bringing the most advanced checkpoint security technology coming to market with a cutting-edge design that lends itself to the innovative atmosphere of this region," said Mark Laustra, vice president global business development and government relations. "International hubs need security solutions that let passengers move smoothly through the security process. ConneCT is designed to minimize the inconvenience associated with security requirements such as the recent electronics ban that slows throughput. ConneCT uniquely provides that level of security."
Airports worldwide have been exploring new types of security lanes and tray return systems intended to streamline the security process. Analogic's ConneCT was engineered to integrate with a wide variety of tray return systems, allowing airports to optimize checkpoints with the tray return system of their choice. Analogic will feature the ConneCT scanner at the Dubai Airport Show 2017, May 15-17, DICEC, Dubai, Booth #6170.
The ConneCT screening system is currently undergoing testing with the Transportation Security Administration (TSA) in the US and has entered European Civil Aviation Conference (ECAC) certification protocol in Europe. Analogic continues to work closely with international certification agencies and airports to bring the ConneCT system to the global market in 2017.
About Analogic - Celebrating 50 Years of Imaging Innovation
Analogic (Nasdaq:ALOG) provides leading-edge healthcare and security technology solutions to advance the practice of medicine and save lives. We are recognized around the world for advanced imaging and real-time guidance technologies used for disease diagnosis and treatment as well as for automated threat detection. Our market-leading ultrasound systems, led by our flagship BK Ultrasound brand, used in procedure-driven markets such as urology, surgery, and point-of-care, are sold to clinical practitioners around the world. Our advanced imaging technologies are also used in computed tomography (CT), magnetic resonance imaging (MRI) and digital mammography systems, as well as automated threat detection systems for aviation security. Analogic is headquartered just north of Boston, Massachusetts. For more information, visit www.analogic.com.
Analogic and the globe logo are registered trademarks of Analogic Corporation. ConneCT is a trademark of Analogic Corporation.
For Further Information, Contact:
Sr. Director of Investor Relations
Coltrin & Associates, Inc.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Analogic Corporation via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference21.11.2017 15:15 | Pressmeddelande
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Smith, Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28th, at 12:00 p.m. EST. The conference will be held at the Lotte New York Palace. A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately two hours after the live presentation and will be archived on the website for approximately 90 days. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and comme
OmniComm Systems Signs Letter of Intent to Acquire Certain Assets of Algorithm and its Subsidiary Algorics21.11.2017 14:00 | Pressmeddelande
Acquisition Will Expand OmniComm's Product Line With Data Analytics and Risk-Based Monitoring Solutions FORT LAUDERDALE, Fla., Nov. 21, 2017 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX:OMCM), a leading global provider of clinical data management technology, and Algorithm, Inc. and its subsidiaries Algorics Ltd. and Algorithm Informatics Pvt. Ltd. (collectively, "Algorics"), have signed a letter of intent ("LOI"), under which OmniComm will acquire certain assets and assume certain liabilities of Algorics, a provider of clinical analytics solutions and software. By combining forces, the companies expect increased operating efficiency, strengthened traction in the maturing risk-based approach solution area, new marketing opportunities and an expanded portfolio of electronic data capture (EDC) solutions for the global clinical trials industry. The transaction would also provide OmniComm with an office in India, a country of growing importance in t
CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs21.11.2017 14:00 | Pressmeddelande
SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the publication of two new papers. These joint publications illustrate the utility of Crown Bioscience's proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies. The research conducted by Crown Bioscience, Eli Lilly and Company and Ball State University was published in two PLOS ONE papers: Peterson et al. Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco model PLOS One 2017;12 (6):e0179856, https://doi.org/10.1371/journal.pone.0179856 Droz et al. Correlation of disease severity with body weight and high fat diet in the FATZO/Pco model PLOS One 2017;1
Port Moresby Stock Exchange (POMSoX) Launches New Nasdaq Trading System21.11.2017 11:31 | Pressmeddelande
NEW YORK and PORT MORESBY, Papua New Guinea, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (NASDAQ:NDAQ) and the Port Moresby Stock Exchange (POMSoX) have announced that POMSoX has gone live with the widely deployed Nasdaq Matching Engine that operates on the Nasdaq Financial Framework platform. The launch of the new trading platform is a result of an upgrade from previous Nasdaq trading technology. The new trading engine will handle the trading of equities in the Papua New Guinea market. POMSoX has been a customer of Nasdaq since 1999. "The Nasdaq trading platform will allow significant innovation in terms of market design and market offerings," said Johnson Kalo, a POMSoX board member said. "We believe the platform will provide strong support for future growth in the PNG market and provide new business opportunities in areas such as market data distribution." "We are pleased to continue to support POMSoX, a longstanding Nasdaq customer," said Robert Frojd, Regional Man
CloudCraze Joins the Pledge 1% Movement, Makes Commitment to Philanthropic Leadership21.11.2017 08:00 | Pressmeddelande
CloudCraze will leverage profit and employee time to improve communities around the world LONDON, Nov. 21, 2017 (GLOBE NEWSWIRE) -- CloudCraze, the enterprise B2B commerce platform built natively on Salesforce, has joined Pledge 1%, a corporate philanthropy movement dedicated to making the community a key stakeholder in every business. Spearheaded by Atlassian, Rally, Salesforce and Tides, Pledge 1% empowers companies to donate 1% of product, 1% of equity, 1% of profit or 1% of employee time to improve communities around the world. CloudCraze is joining an impressive network of entrepreneurs and companies across the globe that have committed to philanthropic efforts through the Pledge 1% movement. By pledging 1% of its profit and employee time, CloudCraze is demonstrating a commitment to philanthropic leadership. "We are incredibly excited that CloudCraze has taken the pledge," said Amy Lesnick, chief executive of Pledge 1%. "CloudCraze can play a pivotal role i
HemChecks avläsare kalibrerad med toppresultat - Regulatorisk20.11.2017 16:18 | Pressmeddelande
HemChecks avläsare kalibrerad med toppresultat Det medicintekniska bolaget HemCheck, som utvecklar ett patientnära test för detektion av hemolys, kan idag meddela att den digitala avläsare som utgör en del av bolagets produktkoncept Helge, kalibrerats med mycket gott resultat. Detta skedde genom studier i egen regi. Avläsaren kan nu färdigställas och produktkonceptet kommer därmed ett steg närmare CE-märkning. Som ett led i att färdigställa bolagets produktkoncept Helge har HemCheck under hösten utfört studier i egen regi med hjälp av blod från frivilliga bloddonatorer. Syftet var att kalibrera avläsaren och på så sätt möjliggöra en patientnära avläsning av hemolys, det vill säga redan på ett tidigt stadium avgöra om blodprovet är användbart och kan ska skickas till analys. -Enkelt utryckt har vi lärt avläsaren att mäta hemolys på våra engångstester. Det är en viktig milstolpe och en stor framgång. Nu känner vi oss redo
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum